Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Treasury Shares (2022 - 2025)

BioXcel Therapeutics has reported Treasury Shares over the past 4 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Treasury Shares at $1.1 million for Q4 2025, down 8.06% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (down 8.06% YoY), and the annual figure for FY2025 was $1.1 million, down 8.06%.
  • Treasury Shares for Q4 2025 was $1.1 million at BioXcel Therapeutics, up from $115000.0 in the prior quarter.
  • Over the last five years, Treasury Shares for BTAI hit a ceiling of $1.8 million in Q3 2024 and a floor of $140.0 in Q1 2025.
  • Median Treasury Shares over the past 4 years was $119000.0 (2022), compared with a mean of $352415.0.
  • Biggest five-year swings in Treasury Shares: crashed 99.81% in 2023 and later soared 190566.67% in 2024.
  • BioXcel Therapeutics' Treasury Shares stood at $1310.0 in 2022, then skyrocketed by 17075.57% to $225000.0 in 2023, then surged by 418.22% to $1.2 million in 2024, then decreased by 8.06% to $1.1 million in 2025.
  • The last three reported values for Treasury Shares were $1.1 million (Q4 2025), $115000.0 (Q3 2025), and $57000.0 (Q2 2025) per Business Quant data.